Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Export

@article{citeulike:2986752, abstract = {The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.}, address = {Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. cwillett@partners.org}, author = {Willett, C. G. and Boucher, Y. and di Tomaso, E. and Duda, D. G. and Munn, L. L. and Tong, R. T. and Chung, D. C. and Sahani, D. V. and Kalva, S. P. and Kozin, S. V. and Mino, M. and Cohen, K. S. and Scadden, D. T. and Hartford, A. C. and Fischman, A. J. and Clark, J. W. and Ryan, D. P. and Zhu, A. X. and Blaszkowsky, L. S. and Chen, H. X. and Shellito, P. C. and Lauwers, G. Y. and Jain, R. K.}, citeulike-article-id = {2986752}, citeulike-linkout-0 = {http://dx.doi.org/10.1038/nm988}, citeulike-linkout-1 = {http://dx.doi.org/10.1038/nm988}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/14745444}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=14745444}, doi = {10.1038/nm988}, issn = {1078-8956}, journal = {Nature medicine}, keywords = {antiangiogenic, bevacizumab, cancer}, month = {February}, number = {2}, pages = {145--147}, posted-at = {2009-03-04 17:11:53}, priority = {4}, title = {Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.}, url = {http://dx.doi.org/10.1038/nm988}, volume = {10}, year = {2004} }

TY - JOUR ID - citeulike:2986752 L3 - citeulike-article-id:2986752 N2 - The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors. IS - 2 JF - Nature medicine SN - 1078-8956 AD - Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. cwillett@partners.org EP - 147 TI - Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. VL - 10 SP - 145 KW - antiangiogenic KW - bevacizumab KW - cancer AU - Willett, CG AU - Boucher, Y AU - di Tomaso, E AU - Duda, DG AU - Munn, LL AU - Tong, RT AU - Chung, DC AU - Sahani, DV AU - Kalva, SP AU - Kozin, SV AU - Mino, M AU - Cohen, KS AU - Scadden, DT AU - Hartford, AC AU - Fischman, AJ AU - Clark, JW AU - Ryan, DP AU - Zhu, AX AU - Blaszkowsky, LS AU - Chen, HX AU - Shellito, PC AU - Lauwers, GY AU - Jain, RK PY - 2004/02// UR - http://dx.doi.org/10.1038/nm988 ER -